🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Inari Medical shares price target cut, retains buy rating

EditorNatashya Angelica
Published 05/02/2024, 12:40 AM
NARI
-

On Wednesday, Canaccord Genuity maintained a Buy rating on Inari Medical Inc. shares (NASDAQ:NARI) but reduced the price target to $55 from the previous $75. The adjustment follows Inari Medical's announcement of its first-quarter results for 2024, which exceeded expectations.

The company reported quarterly revenue of $143.2 million, marking a 23.3% increase year over year. This performance surpassed both Canaccord Genuity and Street estimates.

Inari Medical also updated its full-year 2024 guidance, now anticipating revenue between $592.5 million and $602.5 million, reflecting a 20% to 22% year-over-year growth. This is an upward revision from the previously projected range of $580 million to $595 million.

Despite the strong start in the first quarter, the company's management has conservatively projected its revenue guidance for the remaining year, factoring in the easier comparisons for the second quarter of 2024.

The company's management highlighted its three primary growth drivers: Venous Thromboembolism (VTE) treatments, Emerging Therapies, and international expansion. They detailed plans for commercial expansion, deeper market penetration, and the anticipated release of strong clinical data later in the year. Moreover, Inari Medical is focusing on developing its product portfolio with new offerings such as VenaCor, Artix, and LimFlow, alongside plans for growth outside the United States.

Regarding the Corporate Integrity Agreement (CIA) with the Department of Justice (DOJ), Inari Medical's management stated that the company has not seen any commercial impact from the agreement and does not expect any in the future.

The company is continuing to cooperate with the DOJ on this matter. Canaccord Genuity reaffirms its confidence in Inari Medical's growth prospects and its Buy rating on the stock despite the lowered price target.

InvestingPro Insights

In light of Canaccord Genuity's maintained Buy rating and revised price target for Inari Medical Inc., real-time data from InvestingPro provides additional context for investors. With a market capitalization of $2.16 billion and a notable gross profit margin of 87.67% in the last twelve months as of Q1 2024, Inari Medical's financial health appears robust. The company's impressive gross profit margins are a testament to its operational efficiency and could be a key factor in its long-term growth potential.

Still, investors should be aware that Inari Medical is currently trading near its 52-week low, with its stock price having declined by 20.86% over the last month. This could signal a potential buying opportunity for those who believe in the company's growth drivers and international expansion plans. Moreover, the company's liquid assets exceeding its short-term obligations suggest a solid financial position to weather short-term market fluctuations.

For those looking for a deeper analysis, InvestingPro offers additional InvestingPro Tips, including insights on the company's anticipated net income drop and profitability expectations for the year. Interested investors can find more tips and a comprehensive analysis, including the InvestingPro Fair Value estimate of $32.68 for Inari Medical, at https://www.investing.com/pro/NARI. To further enrich your investment strategy, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With several more InvestingPro Tips available, investors can gain a more nuanced understanding of Inari Medical's financial outlook and market positioning.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.